Following on from a decision by the Indian Patent Office to grant a compulsory licence for Sorafenib Tosylate, the country’s first, against Bayer’s Nexavar, a first-line treatment for liver and kidney cancer, the government of fellow Asian nation Indonesia has taken the unprecedented step of overriding the patents on seven HIV and hepatitis treatments, citing urgent need to improve patient access.
Please login to access this content
Register for FREE increased access on the website – its quick and easy!
As a registered user you will gain quick, easy and instant access to articles on PharmaAfrica.com
Already registered? Click here to sign in
Not a Subscriber? Subscribe to PharmaAfrica.com
Please click here to find out how you can subscribe for full membership and obtain unlimited online access, receive weekly updates and 12 issues of monthly newsletter, PharmaAfrica.